- Recommendation ID
- Botulinum toxin A:- What is the long-term effectiveness, optimal dose and optimal frequency of repeat therapy of botulinum toxin A in women with OAB based on detrusor overactivity including risk of adverse events such as urinary infection and intermittent catheterisation?
- Any explanatory notes
- Why is this important:- There are currently no trials looking at long-term outcomes, quality of life, satisfaction, optimal dose, optimal frequency and long-term adverse effects of botulinum toxin A for women with OAB. Further research into these outcomes will have an impact on future updates of key recommendations within the guideline and would impact on how resources are used within urinary incontinence services. Effective treatment with botulinum toxin A may need repeated injections to remain effective but the frequency of these is not reported in the current evidence. Botulinum toxin A has the potential to cause incomplete bladder emptying resulting in the need for women to perform catheterisation indefinitely. This not only has financial implications but catheterisation and the morbidity associated with it will not always be acceptable to women. Additionally, there are currently no data on whether repeated botulinum toxin A injections alter bladder function.
Source guidance details
- Comes from guidance
- Urinary incontinence in women: management
- Date issued
- September 2013
|Is this a recommendation for the use of a technology only in the context of research?||No|
|Is it a recommendation that suggests collection of data or the establishment of a register?||No|